Regeneron invests further $350 million in Ireland

20 October 2015

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) is investing an additional $350 million in its Limerick Industrial Operations and Product Supply (IOPS) bioprocessing campus in Ireland.

This will add another 200 jobs, bringing the total expected job creation in the Limerick area to 500 jobs and total investment to $650 million by the end of 2017. The extra capacity it needed for the production of drugs such as Regeneron’s successful ophthalmic agent Eylea (aflibercept), marketed with Germany’s Bayer, as well as recently-approved cholesterol-lowerer Praluent (alirocumab), co-developed with France’s Sanofi.

The company acquired the former Dell Computer facility in Limerick and achieved planning approval in April 2014 for its first IOPS site outside of the USA. When the investment was initially announced in December 2013, a $300 million investment with 300 jobs was planned for delivery by the end of 2016. With this expansion of scope, the Limerick IOPS campus will house the largest-scale bulk biologics production facility in Ireland.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK